BioSig Technologies and Streamex Close $15 Million Offering
BioSig Technologies, Inc. is excited to share that it has successfully completed a public offering, raising approximately $15 million. The company, now merged with Streamex Exchange Corporation (NASDAQ: BSGM), focuses on gold tokenization infrastructure, positioning itself as a leader in the industry.
Details of the Offering
The latest offering included 3,852,149 shares of common stock priced at $3.90 each. This strategic move aimed to bolster BioSig’s resources, generating gross proceeds of around $15 million. The funds will primarily be used for purchasing gold bullion, adhering to BioSig’s investment policy, and enhancing the company's operational capital.
Growth and Investment Strategy
Henry McPhie, CEO of BioSig and Co-Founder of Streamex, mentioned that the strong capital strategy they’ve now established will help secure the company’s future in this pivotal phase. With the backing of quality shareholders, BioSig aims to accelerate value creation for investors as it expands within the gold bullion market.
Strategic Partnerships
Clear Street and Needham & Company played vital roles as joint book-running managers in this offering. Their expertise and insights have been instrumental in ensuring a successful outcome for BioSig.
Regulatory Compliance
The public offering was conducted in accordance with a shelf registration statement filed with the Securities and Exchange Commission (SEC). A final prospectus supplement, along with a base prospectus, is available for investors seeking more details about this opportunity.
The Future of Streamex
Streamex is dedicated to building institutional-grade infrastructure that integrates the gold market with blockchain technology. By doing so, it aims to create a gold-denominated treasury and enhance investor access to tokenization.
About BioSig Technologies
As a forefront medical device technology company, BioSig Technologies offers the advanced PURE EP™ Platform. This platform enables electrophysiologists to capture real-time data, free from noise, ensuring precision in ablation treatments for cardiovascular arrhythmias. The effectiveness of the PURE EP™ system presents significant benefits by maximizing procedural efficacy while minimizing costs.
Frequently Asked Questions
What was the total amount raised in BioSig's public offering?
BioSig Technologies raised approximately $15 million through its public offering with Streamex.
What is the purpose of the funds raised from the offering?
The proceeds will be used to purchase gold bullion, support general corporate purposes, and enhance working capital for BioSig Technologies.
Who are the joint book-running managers for the offering?
Clear Street and Needham & Company acted as joint book-running managers for BioSig’s public offering.
What is Streamex's role within BioSig Technologies?
Streamex focuses on bringing the gold market on-chain, utilizing a gold-denominated treasury to promote tokenization and investment opportunities.
How does the PURE EP™ Platform benefit electrophysiologists?
The PURE EP™ Platform allows electrophysiologists to obtain clear, real-time signal data, increasing procedural success while reducing inefficiencies and costs.
